Trazodone Overdose and Accidental Excess Dose: What Every Woman Needs to Know

What Trazodone Is and How It Works

Trazodone belongs to a class called serotonin antagonist and reuptake inhibitors, commonly abbreviated SARI. It is not a benzodiazepine, not a Z-drug, and not a tricyclic antidepressant, though it shares some pharmacological overlap with each group depending on dose. Understanding the mechanism matters for understanding overdose, because the same receptors that make trazodone useful at low doses become sources of toxicity when the drug accumulates.

Receptor-Level Mechanism

At therapeutic doses, trazodone does three things simultaneously. First, it blocks 5-HT2A and 5-HT2C serotonin receptors, which reduces anxious rumination and promotes slow-wave sleep. Second, it weakly inhibits the serotonin transporter (SERT), increasing synaptic serotonin. Third, it antagonizes histamine H1 receptors and alpha-1 adrenergic receptors, which drives its pronounced sedative and blood-pressure-lowering effects.

At supratherapeutic levels, the alpha-1 blockade intensifies dramatically, producing orthostatic hypotension severe enough to cause syncope. The sodium channel effects that emerge at very high plasma concentrations can slow cardiac conduction, widening the QRS complex on ECG in a pattern that resembles tricyclic antidepressant poisoning.

Why the Dose Matters More Than You Think

The dose-response relationship is not linear. A 2005 review by Mendelson in the Journal of Clinical Psychiatry confirmed that off-label sleep doses as low as 25-50 mg already produce measurable alpha-1 blockade, meaning a woman who doubles her sleep dose "just to get better rest" is not simply getting twice the sedation. She is landing on a steeper portion of the alpha-1 and H1 blockade curves.

Sex-Specific Pharmacokinetics

Women metabolize trazodone differently than men. Trazodone is predominantly metabolized by CYP3A4, an enzyme whose activity is modulated by estrogen and progesterone. During the luteal phase of the menstrual cycle, CYP3A4 activity shifts, and peak plasma concentrations of trazodone may be modestly higher than during the follicular phase. This has not been formally studied in large RCTs, which is a real evidence gap you should know about. The data are extrapolated from CYP3A4 substrate studies in women generally, not from trazodone-specific pharmacokinetic trials stratified by cycle phase.

Perimenopausal women who are also using exogenous estrogen (oral or transdermal hormone therapy) may have further variation in CYP3A4 activity. Oral estrogens increase CYP3A4 substrate clearance via hepatic first-pass induction; transdermal estrogens have a smaller hepatic effect. If your hormone therapy route changes, your trazodone exposure may shift too, even without a dose adjustment.

What Counts as an Overdose or Accidental Excess Dose

"Overdose" in clinical toxicology covers a wide range, from a woman who accidentally takes a double bedtime dose to someone who ingests a large quantity in a mental health crisis. The management differs, but the initial steps do not.

Accidental Double Dose

The most common scenario on a women's health platform: you took your trazodone, forgot, and took it again. For most adults, a single accidental doubling of a low sleep dose (say, 50 mg taken twice for a total of 100 mg) will produce increased sedation and possibly a fall on the way to the bathroom. Call Poison Control at 1-800-222-1222 to confirm based on your exact dose and weight, but this scenario is rarely life-threatening in otherwise healthy adults. Do not drive. Do not operate machinery. Stay in bed or on a safe surface.

Moderate Excess Dose

Doses in the 1,000-2,000 mg range are associated with CNS depression, hypotension, and QTc prolongation. A systematic review of trazodone overdose cases found that cardiac arrhythmias, though uncommon, occurred primarily in patients with underlying cardiac disease or co-ingestion of other drugs. This matters for women because cardiovascular disease in women is under-recognized and under-diagnosed, meaning a woman presenting with trazodone excess may have a cardiac substrate she does not know about.

Severe or Intentional Overdose

Doses above 2,000 mg, especially combined with alcohol or other CNS depressants or serotonergic drugs, can produce serotonin syndrome, respiratory depression, and ventricular arrhythmia. This is a medical emergency. Call 911 immediately. Do not wait to see whether symptoms develop.

Symptoms of Trazodone Toxicity by System

Knowing which symptoms correlate with which mechanisms helps you communicate clearly with Poison Control or emergency staff.

Central Nervous System

Excessive sedation is the first and most common sign. This can progress to confusion, ataxia (unsteady gait), and, in severe cases, coma. Trazodone does not typically produce the anticholinergic toxidrome (dry mouth, urinary retention, mydriasis) seen with tricyclics, which helps clinicians distinguish the two. Seizures are rare with trazodone alone but have been reported in overdose cases.

Cardiovascular

QTc prolongation is the main cardiac concern. Trazodone prolongs the QT interval in a dose-dependent fashion, and women already have a baseline longer QTc than men. This is not a minor detail. Sex differences in cardiac ion channel expression mean women are intrinsically more susceptible to drug-induced QT prolongation and torsades de pointes than men of the same weight taking the same dose. This is directly studied physiology, not extrapolation.

Hypotension from alpha-1 blockade can be severe. Orthostatic hypotension leading to falls is a particular risk in older perimenopausal and postmenopausal women, in whom baseline vasomotor instability from declining estrogen already impairs blood pressure regulation.

Serotonin Toxicity

Trazodone used alone rarely causes full serotonin syndrome at any dose. The risk rises sharply when it is combined with other serotonergic agents: SSRIs, SNRIs, MAOIs, tramadol, linezolid, triptans, or even St. John's Wort. The Hunter Criteria for serotonin toxicity include clonus, agitation, diaphoresis, tremor, and hyperthermia. If you or anyone near you develops muscle twitching, fever, and agitation after excess trazodone combined with any of these agents, this is an emergency.

Women with PCOS who are on metformin and also use tramadol for pain, or women taking SSRIs for PMDD who add trazodone for sleep, are in a category that warrants explicit conversation with their prescriber about serotonin load.

Emergency Response: Step-by-Step

Speed matters. Here is what to do in order.

Step 1: Call for Help Before Anything Else

Do not try to induce vomiting. Do not give fluids or food. Call Poison Control (1-800-222-1222) if the person is conscious and responding. Call 911 if the person is unconscious, seizing, or you cannot rouse them. Poison Control is staffed 24 hours a day, seven days a week, and the call is free and confidential.

Tell the operator: the name of the drug, the dose of each tablet, how many tablets are missing from the bottle, when the last known dose was, and any other drugs or alcohol involved.

Step 2: Do Not Leave the Person Alone

Trazodone sedation can deepen over the 1-3 hours after ingestion as absorption continues. A person who seems "just sleepy" can progress to unresponsive. Place them on their side (recovery position) if they are unconscious or vomiting to reduce aspiration risk.

Step 3: At the Emergency Department

Emergency clinicians will obtain an ECG to measure QTc interval, establish IV access, check serum electrolytes (low potassium and magnesium worsen QT prolongation), and monitor cardiac rhythm. Activated charcoal may be given if the patient arrives within 1-2 hours of ingestion and airway is protected. There is no specific antidote for trazodone. Treatment is supportive: IV fluids for hypotension, sodium bicarbonate if QRS widening is present, benzodiazepines for seizures. Physostigmine is not used for trazodone overdose because trazodone does not produce a pure anticholinergic toxidrome.

Who Is at Higher Risk for Severe Toxicity

Not all women face the same overdose risk from the same dose. Several factors increase the danger.

Age and Life Stage

Reproductive years (18-44): Risk is primarily from co-ingestion (alcohol, SSRIs for PMDD or depression, sleep aids) and from inadvertent dose stacking. Women in this group are also more likely to present to emergency departments with self-harm overdose, and trazodone is commonly prescribed in this population for insomnia secondary to depression or anxiety.

Perimenopause (typically 45-55): Vasomotor instability makes alpha-1-mediated hypotension more dangerous. Night sweats and poor sleep are common reasons trazodone is prescribed in this group. Women already on hormone therapy have altered CYP3A4 activity as described above. Cardiac arrhythmia risk is also higher as cardiovascular risk rises with the menopausal transition.

Post-menopause (55+): Falls from orthostatic hypotension can cause hip fractures. Older women are more likely to take multiple medications that interact with trazodone, and renal and hepatic clearance both decline with age, meaning standard doses produce higher plasma concentrations than in younger women.

Co-Existing Conditions

Women with prolonged QTc at baseline, eating disorders (associated with electrolyte abnormalities that worsen QT prolongation), hepatic impairment, or cardiac disease are at meaningfully higher risk of arrhythmia with trazodone excess. Women with PCOS, who have higher rates of metabolic syndrome and obstructive sleep apnea, may have cardiac conduction differences that compound the risk.

Drug Interactions That Matter for Women

• SSRIs or SNRIs (prescribed for PMDD, postpartum depression, perimenopause mood symptoms): serotonin toxicity risk.
• Azole antifungals like fluconazole (commonly used for recurrent vulvovaginal candidiasis): CYP3A4 inhibition raises trazodone plasma levels substantially.
• Oral contraceptives containing ethinyl estradiol: modest CYP3A4 modulation; clinical significance is uncertain but worth noting with your prescriber.
• Antiretrovirals (ritonavir, cobicistat): potent CYP3A4 inhibitors that can double or triple trazodone exposure.

The table below organizes the interactions most relevant to women at different life stages:

| Life Stage | Common Co-Medication | Interaction Type | Clinical Action | |---|---|---|---| | Reproductive years | SSRIs for PMDD | Serotonin additive | Discuss total serotonin load with prescriber | | Reproductive years | Fluconazole (recurrent VVC) | CYP3A4 inhibition, raised trazodone level | Use shorter courses; monitor sedation | | Perimenopause | Oral estrogen (HT) | CYP3A4 induction, may lower trazodone level | Reassess dose if HT route changes | | Post-menopause | Multiple antihypertensives | Additive hypotension | Rise slowly; fall risk counseling | | Any | Alcohol | CNS/respiratory depression additive | Avoid alcohol on trazodone nights |

Pregnancy and Lactation Safety

Pregnancy

Trazodone carries a former FDA Pregnancy Category C designation, meaning animal studies showed adverse effects and adequate human studies are lacking. This category has been replaced by the newer narrative labeling system under the Pregnancy and Lactation Labeling Rule (PLLR), but the underlying data situation has not changed: human evidence is thin.

Available data come from case reports and small observational cohorts, not prospective controlled trials. No consistent pattern of major congenital malformations has been established, but the dataset is too small to confidently rule out teratogenicity. The FDA prescribing information states that trazodone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Untreated depression in pregnancy carries its own serious risks, including preterm birth, low birth weight, and postpartum depression. The decision is not "trazodone vs. Safety." The decision is "trazodone vs. Untreated depression vs. Alternative treatment," and it should be made with your OB-GYN or maternal-fetal medicine specialist, not avoided through patient-driven discontinuation.

If you become pregnant while taking trazodone: Do not stop abruptly. Contact your prescriber within 24 hours to discuss a plan. Abrupt discontinuation of antidepressants in the second or third trimester can cause discontinuation syndrome.

Neonatal effects: There are case reports of neonatal discontinuation syndrome in infants born to mothers taking trazodone near term. Symptoms include irritability, feeding difficulty, and tremor. Neonatology should be informed of maternal trazodone use before delivery.

Lactation

Trazodone is excreted into human breast milk. The estimated relative infant dose is low (below 2% in limited pharmacokinetic studies), which is generally considered acceptable by LactMed and most lactation specialists, but the available data are from small case series rather than strong pharmacokinetic studies. Sedation is the main theoretical infant concern.

If you are breastfeeding and taking trazodone, watch your infant for unusual sedation, difficulty latching, or poor weight gain. Timing the dose immediately after the last evening feed and before the infant's longest sleep interval minimizes the milk concentration during active nursing. Discuss this timing strategy with your prescriber or a certified lactation consultant.

Contraception Considerations

Trazodone is not a known teratogen in the same category as medications like valproate or isotretinoin, so it does not carry a mandated contraception program. Given the limited human pregnancy data, women of reproductive potential who are prescribed trazodone should discuss their contraception status with their prescriber, especially if the underlying indication is depression or PMDD, conditions where pregnancy planning carries additional complexity.

Trazodone for Sleep in Women: The Evidence Base

Off-label prescribing of trazodone for insomnia is now more common than its use for depression, particularly in women. The 2005 Mendelson review in the Journal of Clinical Psychiatry found that despite widespread use, the evidence base for trazodone as a sleep agent was limited, with few large placebo-controlled trials specifically in insomnia patients. Most prescribing was extrapolated from its sedative side-effect profile observed in depression trials.

This matters because women are prescribed trazodone for insomnia at higher rates than men, partly because women have higher rates of insomnia diagnosis across all life stages. Approximately 40% of women report chronic insomnia symptoms compared to 30% of men, and the prescribing gap reflects this. Yet the trials on which dosing confidence is based enrolled predominantly male or mixed-sex samples without sex-stratified outcomes. The evidence gap in women is real. Dosing guidance at 25-100 mg for sleep is based on clinical convention, not on randomized trials in women showing optimal dose-response.

For perimenopausal and postmenopausal women, sleep disruption is often driven by vasomotor symptoms, and addressing the underlying hormonal cause with evidence-based hormone therapy may be more targeted than adding a sedating antidepressant. Cognitive behavioral therapy for insomnia (CBT-I) remains the first-line recommendation per the American College of Physicians before any pharmacotherapy.

Who This Is Right For and Who Should Be Cautious

Women Who May Benefit

• Women with co-occurring depression and insomnia who need a single agent addressing both.
• Women who have failed or cannot tolerate SSRIs but need an antidepressant.
• Postmenopausal women with insomnia who have contraindications to hormone therapy and have not responded to CBT-I.
• Women seeking a non-scheduled (non-controlled) sleep option with lower dependency risk than benzodiazepines or Z-drugs.

Women Who Should Be Cautious or Avoid

• Women with known QTc prolongation or a personal or family history of long QT syndrome.
• Women with eating disorders and electrolyte abnormalities.
• Women taking MAOIs (absolute contraindication; risk of severe serotonin toxicity).
• Women in the first trimester of pregnancy without a compelling need after risk-benefit discussion.
• Women who drink alcohol regularly, given additive CNS depression risk.
• Older postmenopausal women at high fall risk, unless they and their prescriber have explicitly addressed this.

Preventing Accidental Excess Dose: Practical Steps

The most common overdose scenario is not intentional. It is a tired woman who cannot remember if she took her tablet. Three habits dramatically reduce the risk:

Use a dated pill organizer or a medication tracking app that requires confirmation before logging the dose. Keep trazodone in the original labeled bottle, not a loose container. Safe storage and disposal of medications reduces the risk of accidental ingestion by children and reduces availability in mental health crises.

If you are struggling with thoughts of self-harm, the 988 Suicide and Crisis Lifeline is available by call or text at 988. Your prescriber can also work with you on keeping only a limited supply at home.

A Clinical Note on Mental Health Crises and Overdose Intent

Women are more likely than men to attempt suicide by overdose rather than by more immediately lethal means. This does not mean overdose is less serious. Trazodone overdose in the context of a mental health crisis requires psychiatric evaluation in addition to medical management. Emergency departments in most states have protocols for this, and you have the right to ask for a social worker or psychiatric consultant during your ED visit.

If you are a prescriber reading this article on behalf of a patient: limiting dispensed quantity, involving a support person in safe storage, and explicitly asking about suicide risk at each visit are all evidence-supported strategies for reducing medication overdose risk in high-risk populations.